Jury rules against Merck in second NJ Vioxx trial

Merck has been handed a setback in a key Vioxx lawsuit. A New Jersey jury awarded $47.5 million for a plaintiff. It was the second time for the case to go to a jury. Merck won the first case, but an appeals court threw out the verdict after deciding that Merck had excluded new evidence that had later come to light. The jury decided that Merck had committed consumer fraud and had intentionally suppressed or concealed material information from physicians. Merck says it will appeal the decision as it faces thousands of suits from other plaintiffs alleging that Vioxx had harmed them.

- read the Irish Times' report on the trial

ALSO: Former CMS administrator Mark McClellan says that the safety issues surrounding Vioxx could have been discovered much sooner if the FDA had mined insurers' big drug databases for more information on drugs. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.